Deschloroketamine
The following information was compiled in October 2025 and is subject to change as new research is conducted and as new information becomes available:
Description: Deschloroketamine is a novel hallucinogen and is categorized as an arylcyclohexylamine and a structural analog of ketamine. Deschloroketamine was originally synthesized as an immunomodulation agent for the treatment of infections; however, has since been identified in seized drug materials and for sale on online forums.1,2 Deschloroketamine was first identified by our laboratory in July 2025 and confirmed after acquiring standard reference material.
Sample Source: In Collaboration with StreetCheck
Sample Appearance: Colorless plastic bag containing residue
Pharmacology: Deschloroketamine is reported to be an antagonist at the N-methyl-D-aspartate (NMDA) receptor3.
Toxicology: Deschloroketamine has been detected in at least five toxicology cases to date at the CFSRE.
Drug Materials: Deschloroketamine has been detected in five drug materials to date at the CFSRE.
Demographics / Geographics: Drug materials originated from New England, Pennsylvania, and Illinois. Deschloroketamine was identified alone and alongside ketamine.
Legal Status: Deschloroketamine is not currently scheduled in the United States.
- Class:
- Hallucinogen
- Appearance:
- Colorless plastic bag containing residue
- Formula:
- C13H17NO
- MW:
- 203.3
- [M+]:
- 203
- [M+H]+:
- 204.1383
- IUPAC:
- 2-(methylamino)-2-phenyl-cyclohexanone
- Report Date:
- October 31, 2025
